Burcon Nutrascience Advances Plant-Based Protein Strategy with Milestone Production and Strategic Partnership

Burcon Nutrascience Corporation has achieved notable progress in its plant-based protein strategy during the third quarter of 2025, positioning itself for potential market expansion in the alternative protein industry. The company successfully initiated commercial production of its canola protein isolate and established a robust sales pipeline with over 100 prospective customers evaluating its protein products.

Through a strategic partnership with ProMan, Burcon secured a capital-light approach to facility acquisition and operation. This collaboration enables the company to maintain production control while minimizing direct capital investment. The partnership anticipates first-year sales between $1 million and $3 million, with projected double-digit revenue growth in the second year and potential gross margins exceeding 50% as production capacity increases.

The company has diversified its product portfolio by launching next-generation protein isolates, including Peazazz® pea protein and Puratein® canola protein for egg replacement applications. Additionally, Burcon introduced Solatein™ sunflower protein isolate, expanding its market reach across multiple protein segments.

Financially, Burcon generated $0.06 million in revenues during the quarter, marking its first revenue recognition. The company's net loss narrowed to $1.8 million, compared to $2.0 million in the previous year. A successful rights offering raised $9.43 million, providing approximately $10 million in pro-forma cash balance and ensuring sufficient liquidity for ongoing operations.

The company sees substantial market potential across protein segments, including estimated total addressable markets of $70-116 million for soy protein isolates, $215-392 million for pea proteins, and $68-113 million for canola proteins. These projections suggest significant growth opportunities in the alternative protein landscape.

Stonegate Capital Partners values Burcon using a discounted cash flow model, establishing a valuation range between $1.15 and $1.43 per share, with a midpoint of $1.27, reflecting the company's strategic advancements and market potential.